Evaxion announces plan to implement ads ratio change

Copenhagen, denmark, december 30, 2024 - evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today announced that it plans to change the ratio of its american depositary shares (“adss”) to its ordinary shares, dkk 1 nominal value (the “ads ratio”), from the current one (1) ads representing ten (10) ordinary share to a new ads ratio of one (1) ads representing fifty (50) ordinary shares (the “ads ratio change”). the ads ratio change is expected to become effective on or about january 13, 2025, u.s. eastern time (the “effective date”).
EVAX Ratings Summary
EVAX Quant Ranking